Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 9/20 | 0.34 |
| ▸ | IDH2 | P48735 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 6/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | LIMK2 | P53671 | 5/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021496 | 1.00 | LATS1 (0.38) | LATS1LATS2IDH1IDH2NPC1 | |
| SCHEMBL4021324 | 1.00 | LATS1 (0.38) | LATS1LATS2IDH1IDH2NPC1 | |
| SCHEMBL13901882 | 0.94 | LATS1 (0.38) | LATS1LATS2IDH1IDH2NPC1 | |
| SCHEMBL14404833 | 0.92 | LATS1 (0.37) | LATS1LATS2IDH1IDH2NPC1 | |
| SCHEMBL5538104 | 0.87 | LATS1 (0.34) | LATS1LATS2IDH1IDH2LIMK1 | |
| SCHEMBL4028514 | 0.85 | CYP1A2 (0.43) | IDH1IDH2NPC1RAB9ALIMK1 | |
| SCHEMBL4022692 | 0.85 | CYP1A2 (0.43) | IDH1IDH2NPC1RAB9ALIMK1 | |
| SCHEMBL4017695 | 0.85 | CYP1A2 (0.43) | IDH1IDH2NPC1RAB9ALIMK1 | |
| SCHEMBL13869990 | 0.85 | LATS1 (0.36) | LATS1LATS2IDH1IDH2NPC1 | |
| SCHEMBL4019003 | 0.85 | LIMK1 (0.38) | LATS1LATS2LIMK1MAPK14LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | claimed |
| EP-1891052-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | Wyeth (US) | 2008-02-27 | — | — | EP | claimed |
| US-7244736-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-07-17 | — | — | US | claimed |
| WO-2006138180-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | WYETH (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | claimed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-7244736-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2006138180-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | disclosed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | LATS1 731/4885LATS2 870/4885IDH1 186/4885 |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | TUBB1, TUBB6, TUBB | LATS1 1434/4885LATS2 1854/4885IDH1 150/4885 |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | LATS1 3386/4885LATS2 3859/4885IDH1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.